Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Patrick K. Reville"'
Autor:
Rebecca S. S. Tidwell, Sa A. Wang, Naval Daver, Musa Yilmaz, Yesid Alvarado, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Garcia-Manero, Nitin Jain, Nicholas J. Short, Steven M. Kornblau, Gautam Borthakur, Rabiul Islam, Hagop M. Kantarjian, Patrick K. Reville, Marina Konopleva
Publikováno v:
Lancet Haematol
Summary Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy has been shown to improve overall survival in older (aged 75 years or older) and unfit patients with newly diagnosed acute myeloid leukaemia. The aim of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d51d3854846c1936e9e71a1b7fa758e
https://europepmc.org/articles/PMC8884174/
https://europepmc.org/articles/PMC8884174/
Autor:
Courtney D. DiNardo, Maro Ohanian, Zeev Estrov, Patrick K. Reville, Prithviraj Bose, Sa A. Wang, Michael Andreeff, Farhad Ravandi, Musa Yilmaz, Naval Daver, Lucia Masarova, Hagop M. Kantarjian, Tapan M. Kadia, Yesid Alvarado, Guillermo Garcia-Manero, Nicholas J. Short, Rebecca S. S. Tidwell, Guillermo Montalban-Bravo, Nitin Jain, Gautam Borthakur, Elias Jabbour, Steven M. Kornblau, Marina Konopleva
Publikováno v:
Blood. 136:7-9
Background Addition of the BCL2 inhibitor venetoclax to lower intensity therapy improved survival (OS) for older and unfit patients with newly diagnosed AML. We have previously reported the safety and efficacy of the nucleoside analogue cladribine co
Autor:
Lianchun Xiao, Sanam Loghavi, Marina Konopleva, Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur, Gheath Alatrash, Elias Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, Caitlin R. Rausch, Hagop M. Kantarjian, Maro Ohanian, Jorge E. Cortes, Farhad Ravandi
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Autor:
Patrick K. Reville, Tapan M. Kadia
Publikováno v:
Current treatment options in oncology. 21(4)
There is increasing awareness that AML is a widely heterogeneous disease, not only based on clinical characteristics and demographics of the patients we treat but also based on the genomics of the disease. Wider accessibility to next-generation DNA s
Autor:
Elias Jabbour, Koichi Takahashi, Kapil N. Bhalla, Guillermo Garcia-Manero, Rashmi Malla, Naval Daver, Caitlin R. Rausch, Naveen Pemmaraju, Nitin Jain, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Patrick K. Reville, Michael Andreeff, Hagop M. Kantarjian, Maro Ohanian, Guillermo Montalban-Bravo, Gautam Borthakur, Kelly Marek, Nicholas J. Short, Koji Sasaki, Alessandra Ferrajoli, Ghayas C. Issa, Tapan M. Kadia, Mark Brandt, Courtney D. DiNardo
Publikováno v:
Blood. 138:367-367
Background The combination of venetoclax and 5-azacytidine (5-AZA) for older and unfit patients with newly diagnosed AML has led to significant improvements in remission rates and survival compared to 5-AZA alone. We previously reported encouraging r
Autor:
Patrick K. Reville, Zeev Estrov, Sherry Pierce, Srdan Verstovsek, Michael Andreeff, Alessandra Ferrajoli, Naveen Pemmaraju, Tapan M. Kadia, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Koji Sasaki, Maro Ohanian, Guillermo Garcia-Manero, Courtney D. DiNardo, Hagop M. Kantarjian, Graciela M. Nogueras González, Gautam Borthakur, Nitin Jain, Naval Daver
Publikováno v:
Blood. 136:44-45
Background Recent advances have led to higher response rates and improved survival in patients with newly diagnosed AML. However, early death, lack of response, and long term leukemia-free survival remain important challenges. Early mortality in AML
Autor:
Tapan M. Kadia, Maro Ohanian, Elias Jabbour, Farhad Ravandi, Courtney D. DiNardo, Michael Andreeff, Gautam Borthakur, Carlos E. Bueso-Ramos, Koji Sasaki, Hussein A. Abbas, Guillermo Garcia-Manero, Sherry Pierce, Marina Konopleva, Patrick K. Reville, Hagop M. Kantarjian, Nicholas J. Short, Naval Daver, Alexis Geppner
Publikováno v:
Blood. 136:25-26
Background Myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). While MS in the setting of concomitant medullary acute myeloid leukemia (AML) is relatively well described, much less is known about patients prese
Autor:
Elisabeth Paietta, Fangxin Hong, Brad S. Kahl, Kyung Mann Kim, Vaishalee P. Kenkre, Bartosz Grzywacz, Erik A. Ranheim, Patrick K. Reville, Lakeesha Carmichael, Eneida A. Mendonça, Amy K. Erbe, Wei Wang, Paul M. Sondel, Sandra J. Horning, Anna Hoefges, Yiqiang Song, Songwon Seo, Jeffrey S. Miller, Randy D. Gascoyne, Jacquelyn A. Hank
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-
Autor:
Patrick K. Reville, Sandesh Parajuli
Publikováno v:
Kidney Transplant Management ISBN: 9783030001315
Treatment option for patients with end stage renal disease (ESRD) include dialysis and kidney transplantation. Patients with ESRD are at an increased risk for cardiovascular events, mortality and hospitalization. Kidney transplantation is considered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e1ab8fa5e1a8e407cacdabcf4a00e6c
https://doi.org/10.1007/978-3-030-00132-2_2
https://doi.org/10.1007/978-3-030-00132-2_2
Autor:
Susan L. Cohn, Stephen D. Gillies, Ralph A. Reisfeld, Julie R. Park, Wei Wang, Alice L. Yu, M. Fevzi Ozkaynak, Patrick K. Reville, Jacquelyn A. Hank, Michael D. Hogarty, Wendy B. London, Andrew L. Gilman, Paul M. Sondel, Yiqiang Song, Arlene Naranjo, Lakeesha Carmichael, Mitchell B. Diccianni, Amy K. Erbe, John M. Maris, Katherine K. Matthay, Dustin Hess, KyungMann Kim, Eneida A. Mendonça
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 1
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re